NeuroDerm Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Subsidiary
- Established
- 2003-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.neuroderm.com
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 381
- Registration Number
- NCT04006210
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Rocky Mountain Movement Disorders Center, Englewood, Colorado, United States
🇺🇸Visionary Investigators Network, Aventura, Florida, United States
A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
- Conditions
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- NeuroDerm Ltd.
- Registration Number
- NCT03462043
- Locations
- 🇮🇹
91601, Roma, Italy
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- NeuroDerm Ltd.
- Registration Number
- NCT02782481
- Locations
- 🇮🇱
Haddasah Ein Kerem Medical center, Jerusalem, Israel
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT02726386
- Locations
- 🇺🇸
Parkinsons Disease Treatment Center of Southwest Florida, Port Charlotte, Florida, United States
🇮🇹IRCCS San Raffaele Pisana, Rome, Italy
🇺🇸Henry Ford Hospital, West Bloomfield, Michigan, United States
A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT02604914
- Locations
- 🇬🇧
Quotient Clinical LTD, Ruddington, Nottingham, United Kingdom
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT02577523
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸QUEST Research Institute, Farmington Hills, Michigan, United States
A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT02486432
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02096601
- Locations
- 🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱Hadassah Medical Center, Jerusalem, Israel
A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01883505
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱Tel Aviv Medical Center, Tel Aviv, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-11-14
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- NeuroDerm Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT01725802
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel